These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1449 related articles for article (PubMed ID: 23922182)

  • 1. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
    Zalesak M; Siu K; Francis K; Yu C; Alvrtsyan H; Rao Y; Walker D; Sander S; Miyasato G; Matchar D; Sanchez H
    Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):567-74. PubMed ID: 23922182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
    Graham DJ; Reichman ME; Wernecke M; Zhang R; Southworth MR; Levenson M; Sheu TC; Mott K; Goulding MR; Houstoun M; MaCurdy TE; Worrall C; Kelman JA
    Circulation; 2015 Jan; 131(2):157-64. PubMed ID: 25359164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management services.
    Atay JK; Fanikos J; Barnes GD; Ehle M; Coatney J; Piazza G; Froehlich JB; Goldhaber SZ
    Am J Cardiol; 2013 Aug; 112(3):387-9. PubMed ID: 23647794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
    Chevalier J; Delaitre O; Hammès F; de Pouvourville G
    Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex Differences in Dabigatran Use, Safety, And Effectiveness In a Population-Based Cohort of Patients With Atrial Fibrillation.
    Avgil Tsadok M; Jackevicius CA; Rahme E; Humphries KH; Pilote L
    Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):593-9. PubMed ID: 26508666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study.
    Larsen TB; Rasmussen LH; Gorst-Rasmussen A; Skjøth F; Lane DA; Lip GY
    Am J Med; 2014 Dec; 127(12):1172-8.e5. PubMed ID: 25193361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis.
    Ali A; Bailey C; Abdelhafiz AH
    Age Ageing; 2012 Sep; 41(5):681-4. PubMed ID: 22378612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.
    Brunetti L; Chen C; White J
    Consult Pharm; 2014 Mar; 29(3):169-78. PubMed ID: 24589766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.
    Hohnloser SH; Oldgren J; Yang S; Wallentin L; Ezekowitz M; Reilly P; Eikelboom J; Brueckmann M; Yusuf S; Connolly SJ
    Circulation; 2012 Feb; 125(5):669-76. PubMed ID: 22215856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation.
    Palamaner Subash Shantha G; Bhave PD; Girotra S; Hodgson-Zingman D; Mazur A; Giudici M; Chrischilles E; Vaughan Sarrazin MS
    Circ Cardiovasc Qual Outcomes; 2017 Apr; 10(4):. PubMed ID: 28408716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation.
    Chevalier J; Giroud M; de Pouvourville G
    Cerebrovasc Dis; 2013; 35(4):320-6. PubMed ID: 23615428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
    Villines TC; Schnee J; Fraeman K; Siu K; Reynolds MW; Collins J; Schwartzman E
    Thromb Haemost; 2015 Nov; 114(6):1290-8. PubMed ID: 26446456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
    Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.
    Oldgren J; Alings M; Darius H; Diener HC; Eikelboom J; Ezekowitz MD; Kamensky G; Reilly PA; Yang S; Yusuf S; Wallentin L; Connolly SJ;
    Ann Intern Med; 2011 Nov; 155(10):660-7, W204. PubMed ID: 22084332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.
    Hijazi Z; Hohnloser SH; Oldgren J; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Reilly PA; Siegbahn A; Yusuf S; Wallentin L
    Circulation; 2014 Mar; 129(9):961-70. PubMed ID: 24323795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of bleeding with dabigatran in atrial fibrillation.
    Hernandez I; Baik SH; Piñera A; Zhang Y
    JAMA Intern Med; 2015 Jan; 175(1):18-24. PubMed ID: 25365537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
    Abraham NS; Singh S; Alexander GC; Heien H; Haas LR; Crown W; Shah ND
    BMJ; 2015 Apr; 350():h1857. PubMed ID: 25910928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.
    Nagarakanti R; Ezekowitz MD; Oldgren J; Yang S; Chernick M; Aikens TH; Flaker G; Brugada J; Kamensky G; Parekh A; Reilly PA; Yusuf S; Connolly SJ
    Circulation; 2011 Jan; 123(2):131-6. PubMed ID: 21200007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 73.